Oral Drug Delivery Videos

  1. Developing And Manufacturing Minitablets To Extend Drug Lifecycle 1/27/2025

    Pharmaceutical companies should leverage oral minitablets to extend drug lifecycles, optimize dosing, and improve patient-centric solutions while overcoming manufacturing challenges.

  2. When And How To Use A UFMEA During Device Design 12/11/2024

    When and how might using a uFMEA (Use Failure Mode Effects Analysis) tool benefit biopharma companies addressing regulatory expectations for analyses of risk and/or human factors? In this segment of the Drug Delivery Leader Live event Human Factors Risk Analysis: Leveraging URRA And UFMEA Tools, Natalie, Abts, head of human factors engineering at Genentech, and Shannon Hoste, chief scientific officer at Pathway for Patient Health, discuss potential differences in the contexts, purposes, and degrees of detail in information presented for review.

  3. Scaling Up A Revolutionary Amorphous Solid Dispersion Platform 3/19/2024

    Process parameter and quality attribute relationships, including those for typical pre- and post-ASD unit operations, will be explored in the context of real-world examples.

  4. Defying Dysphagia Via Gel-Based Delivery With Gelteq's Nathan Givoni 1/6/2025

    Patients suffering from dysphagia, or difficulty swallowing, have historically faced limited options for how they receive medications and what kinds can be effectively delivered to them. In this episode of Sit and Deliver, host Tom von Gunden speaks with Gelteq CEO Nathan Givoni about advances in gel-based oral delivery that would allow patients to overcome the challenges dysphagia presents. 

  5. Management Responsibility and the New QMSR 7/11/2024

    What is management’s responsibility in the implementation of approaches to the new QMSR? In this segment of the Drug Delivery Leader Live event New FDA QMSR: Its Role in Part 4 Compliance for Combination Products, consultant Laurie Auerbach of Compliance Prodigies underscores the criticality of management commitment to and engagement in the process.

  6. Advances In Oral GLP-1 Analogs For Obesity 9/12/2024

    Discover how these groundbreaking Oral GLP-1 Analogs therapies are reshaping obesity management and addressing key challenges in formulation and delivery.

  7. Rapid Development Of Amorphous Solid Dispersions For Bioavailability

    See how an amorphous solid dispersion (ASD) of acalabrutinib was designed using in vitro studies and in silico modeling. Understand how ASD formulations can enhance bioavailability.

  8. Identify And Mitigate Absorption Risks With PBPK Modeling 3/12/2024

    See how PBPK models combined with custom and off-the-shelf in vitro tools and solubility enhancement expertise can reduce the need for drug product reformulation or repeated preclinical or clinical studies.

  9. What Types Of Products Are Assessed With A URRA? 12/11/2024

    What types of products in development may need to be assessed in accordance with the FDA’s URRA (Use-Related Risk Analysis) guidance? In this segment of the Drug Delivery Leader Live event Human Factors Risk Analysis: Leveraging URRA And UFMEA Tools, Natalie, Abts, head of human factors engineering at Genentech, describes several common scenarios that illustrate when a URRA approach may or may not be needed.

  10. Next Generation Drug And Biologics Delivery Technologies 5/23/2025

    In this segment of the Drug Delivery Leader Live online event, Innovations In Drug Delivery: Opportunities For Enhancing Familiar, Mature Approaches, host Fran DeGrazio asks panelists James Wabby of biopharmaceutical company AbbVie and Carolyn Dorgan and Courtney Evans of device consultancy Suttons Creek to comment on trends and advances they anticipate in the next phase of delivery development. Those include combination therapies, nanotechnology, reconstitution, and microfluidics.